• Acne
  • Actinic Keratosis
  • Aesthetics
  • Alopecia
  • Atopic Dermatitis
  • Buy-and-Bill
  • COVID-19
  • Case-Based Roundtable
  • Chronic Hand Eczema
  • Drug Watch
  • Eczema
  • General Dermatology
  • Hidradenitis Suppurativa
  • Melasma
  • NP and PA
  • Pediatric Dermatology
  • Pigmentary Disorders
  • Practice Management
  • Precision Medicine and Biologics
  • Prurigo Nodularis
  • Psoriasis
  • Psoriatic Arthritis
  • Rare Disease
  • Rosacea
  • Skin Cancer
  • Vitiligo
  • Wound Care

Article

This Week in Aesthetics: June 28 – July 2

Author(s):

This week in aesthetics, we highlight the FDA approval of Restylane Contour, a guide to Aesthetics Biomedical’s upcoming “The Evolution of Aesthetics” symposium, and more.

This week in aesthetics, Advanced Aesthetic Technologies announces the start of the Algeness VL clinical trial in China, Galderma receives Restylane Contour FDA approval for cheek augmentation, we give a guide to Aesthetics Biomedical’s upcoming “The Evolution of Aesthetics” symposium, and a study compares the results of single-plane vs double-plane MFU-V for upper arm skin laxity.

Algeness VL Clinical Trial Begins

Advanced Aesthetic Technologies, Inc, announces start of Algeness VL clinical trial in China seeking future market approval.

Restylane Contour Receives FDA Approval

Galderma receives Restylane Contour FDA approval for cheek augmentation and correction of midface contour deficiencies.

A Guide to ABM’s “The Evolution of Aesthetics” Symposium

With in-person conferences coming out of the shadows and into the light once again, we detail a guide to Aesthetics Biomedical’s “Perspectives. The Evolution of Aesthetics” symposium happening July 24.

Single-Plane vs Double-Plane MFU-V for Upper Arm Skin Laxity

A study compared the results of single-plane vs double-plane MFU-V for upper arm skin laxity treatment.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

© 2025 MJH Life Sciences

All rights reserved.